Compositions comprising Lilium martagon extracts and uses thereof

ABSTRACT

Provided are compositions comprising an extract of  Lilium martagon  and a carrier. Also provided are methods of lightening the skin comprising the step of applying to skin in need of skin lightening treatment an extract of  Lilium martagon.

FIELD OF INVENTION

The present invention relates to compositions comprising plant extractsfor use on skin. More specifically, it relates to compositionscomprising extracts of Lilium martagon for lightening the skin.

DESCRIPTION OF RELATED ART

A variety of products for lightening the skin are known in the art. Inparticular, products intended to lighten the skin, reduce uneven skinpigmentation and the appearance of pigmented spots (e.g. age spots,freckles, etc.), and/or otherwise treat conditions such ashyperpigmentation, discoloration, melasma, yellowing, and the like areknown. However, many of such products are disadvantageous in that theytend to have low efficacy and/or exhibit undesirable toxicity orirritation in use. Accordingly, there is a need for new skin lighteningmaterials.

Lilium martagon is a member of family Liliaceae with genus Lilium. Thegenus Lilium contains about 110 plants widespread all over the world.Lilium martagon is one such species which is extensively grown inNorthern Asia and Europe. Traditionally the bulbs from Lilium martagonor from other lilies are used as food like potatoes. The bulbs are alsodescribed for use as expectorant, diuretic, and emollient [Plants for afuture database: www.pfaf.org].

The present invention relates to the unexpected discovery that extractsof Lilium martagon (Turk's cap lily) plant are unexpectedly beneficialfor inhibiting melanin synthesis in skin epidermal tissues and forlightening skin.

SUMMARY OF THE INVENTION

Applicants have discovered unexpectedly that extracts of Lilium martagonmay be used in compositions, preferably skin care compositions, andmethods for skin lightening.

In particular, applicants have tested various Lilium martagon extractsand have discovered that such extracts exhibit significant andunexpected skin lightening properties. More specifically, as detailed inthe Examples herein, applicants have measured the UVB-inducedmelanogenesis inhibition activity associated with Lilium martagonextracts and discovered that such extracts exhibit significantUVB-induced melanogenesis inhibition activity (known in the art to beassociated with skin lightening). In addition, applicants have measuredthe lightening properties (ΔL) of the present extracts on skinequivalent materials and, as shown in the Examples, the extractsprovided significant benefits in lightening the skin.

Accordingly, in one aspect, the present invention relates to acomposition comprising extracts of Lilium martagon and a carrier.

In another aspect, the present invention relates to a method forlightening the skin by administering topically to a skin in need of suchtreatment, a composition comprising effective amounts of extracts ofLilium martagon.

DESCRIPTION OF THE INVENTION

As used herein, the term “lightening the skin” refers generally tolightening, brightening, whitening, and/or evening of the skin tone,skin color, and/or shade of skin, and/or to the reduction in sallowness,and/or to the lightening and/or fading of hyperpigmented marks and/orlesions including, but not limited to, pigmented spots, melanin spots,age spots, sun spots, senile lentigos, freckles, lentigos simplex,pigmented solar keratosis, seborrhoeic keratosis, melasma, acne marks,post-inflammatory hyperpigmentation, lentigines, ephelides, combinationsof two or more thereof and the like. In certain embodiments, “lighteningthe skin” also refers to increased skin radiance, glow, translucencyand/or luminescence and/or obtaining a more radiant, glowing,translucent or luminous skin tone appearance or a less yellow or sallowskin tone. In certain preferred embodiments, “lightening the skin”refers to lightening and evening the skin tone, increasing skin radianceand/or lightening age spots.

As used herein, the term “skin in need of skin lightening treatment”refers generally to skin that exhibits one or more property selectedfrom the group consisting of: skin having a measured Individual TypologyAngle (ITA) value below 41 as determined per the COLIPA GUIDELINE:GUIDELINE FOR THE COLORIMETRIC DETERMINATION OF SKIN COLOUR TYPING ANDPREDICTION OF THE MINIMAL ERYTHEMAL DOSE (MED) WITHOUT UV EXPOSUREpublished in 2007, which is incorporated herein by reference and furtherdescribed below, darkened and/or sallow skin, including skin darkened byUV, skin with uneven skin tone, or skin with one or more hyperpigmentedmarks and/or lesions including, but not limited to, pigmented spots,melanin spots, age spots, sun spots, senile lentigos, freckles, lentigossimplex, pigmented solar keratosis, seborrhoeic keratosis, melasma, acnemarks, post-inflammatory hyperpigmentation, lentigines, ephelides,combinations of two or more thereof and the like. In the COLIPAguidelines, skin color is defined function of the ITA value as: verylight skin >55; Light skin 41-55, Intermediate 28-41, and Tan skin <28.In certain preferred embodiments, “skin in need of skin lightening”refers to individuals with a skin having an ITA value of less than 41,such as about 40 or less, about 35 or less, about 30 or less, or morepreferably about 28 or less. In certain other preferred embodiments, thepresent invention is directed to compositions and methods for use onskin in need of skin lightening treatment selected from sallow and/ordarkened skin. In certain other preferred embodiments, the presentinvention is directed to compositions and methods for use on skin inneed of skin lightening treatment selected from the group consisting ofage spots, freckles, marks left after acne, and combinations of two ormore thereof.

As used herein, unless otherwise specified, all percentages ofingredients in compositions are weight percent of active/solidsingredient based on the total weight of composition.

As used herein, a composition that is “essentially free” of aningredient means the composition that has about 2% or less of thatingredient by weight based on the total weight of the composition.Preferably, a composition that is essentially free of an ingredient hasabout 1% or less, more preferably about 0.5% or less, more preferablyabout 0.1% or less, more preferably about 0.05 or less, more preferablyabout 0.01% or less by weight based on the total weight of compositionof the ingredient. In certain more preferred embodiments, a compositionthat is essentially free of an ingredient is free of the ingredient,i.e. has none of that ingredient in the composition.

As used herein, “cosmetically/dermatologically acceptable” means thatthe ingredients which the term describes are suitable for use in contactwith tissues (e.g., the skin or hair) without undue toxicity,incompatibility, instability, irritation, allergic response, and thelike.

As used herein, the term “safe and effective amount” means an amount ofthe extract or of the composition sufficient to induce the desiredeffect, but low enough to avoid serious side effects. The safe andeffective amount of the compound, extract, or composition will vary withe.g. the age, health and environmental exposure of the end user, theduration and nature of the treatment, the specific extract, ingredient,or composition employed, the particular pharmaceutically-acceptablecarrier utilized, and like factors.

Any suitable extracts of the whole plant, flower, stem, leaves and/orbulb of Lilium martagon may be used in accord with the presentinvention. Suitable extracts may be derived from live or dried plant,small cuttings or other portions thereof, and the like.

Suitable extracts of Lilium martagon whole plant, flower, stem, leavesand/or bulb may be obtained using conventional methods including, butnot limited to, direct extraction of material from the biomass bygrinding, macerating, pressing, squeezing, mashing, centrifuging, and/orprocesses such as cold percolation, agitation/distillation, microwaveassisted extraction, supercritical/subcritical CO₂ compressed gasextraction with or without polar modifiers, pressurized solventextraction, accelerated solvent extraction, pressurized or normal hotwater extraction, surfactant assisted pressurized hot water extraction,oil extraction, membrane extraction, Soxhlet extraction, the gold fingerdistillation/extraction and/or processes disclosed, for example, in U.S.Pat. Nos. 7,442,391, 7,473,435, and 7537791 to Integrated BotanicalTechnologies, LLC, incorporated herein by reference, and the like, or byother methods such as solvent extraction, and the like. Any of a varietyof solvents including polar solvents, non-polar solvents, orcombinations of two or more thereof may be used in methods of comprisingsolvent extraction. Suitable polar solvents include polar inorganicsolvents such as water and the like, polar organic solvents such asalcohols and corresponding organic acids, for example C₁-C₈ alcoholsincluding methanol, ethanol, propanol, butanol, and the like and organicacids, including acetic acid, formic acid, propanoic acid, and the like,polyols and glycols, including C₁-C₈ polyols/glycols and the like, andcombinations of two or more thereof. Suitable non-polar solvents includenon-polar organic solvents such as alkanes, including C₁-C₈ alkanes,cycloalkanes, including C₁-C₈ alkanes, alkyl ethers, including C₁-C₈alkyl ethers, Petroleum ethers, ketones, including C₁-C₈ ketones,methylene chloride, ethyl acetate, xylene, toluene, chloroform,vegetable oil, mineral oil and the like. In another embodimentextraction may be obtained by non-polar solvents described above orsupercritical fluid extraction with or without a polar modifier such asC₁-C₈ alcohols, water, C₁-C₈ polyols/glycols or C₁-C₈ organic acids.

In certain preferred embodiments, the extract comprises a non-polarextract prepared by extracting from fresh freeze dried flowers using anon-polar solvent comprising one or more C₁-C₈ alkanes, C₁-C₈cycloalkanes, C₁-C₈ alkyl ethers, and/or chloroform, more preferably oneor more C₁-C₈ alkanes and/or chloroform. In certain more preferredembodiments, the non-polar extract is extracted from Lilium martagonflower using hexanes, chloroform or a mixture thereof. In even morepreferred embodiments, the non-polar extract is extracted from Liliummartagon flower using hexanes. In even more preferred embodiments, thenon-polar extract is extracted from Lilium martagon flower usingchloroform.

In certain preferred embodiments, the extract of the invention comprisesa polar extract prepared by extracting from fresh freeze dried flowersusing a polar solvent comprising water, C₁-C₈ alcohols, C₁-C₈ polyols,C₁-C₈ glycols, and combinations of two or more thereof. In certain morepreferred embodiments, the polar extract is an aqueous extract extractedfrom Lilium martagon flower using water.

In certain other preferred embodiments, the extract of the inventioncomprises a combination of polar and non-polar extracts of from Liliummartagon flower.

In certain preferred embodiments, the extract comprises a non-polarextract prepared by extracting from Lilium martagon bulb using anon-polar solvent comprising one or more C₁-C₈ alkanes, C₁-C₈cycloalkanes, C₁-C₈ alkyl ethers, and/or chloroform, more preferably oneor more C₁-C₈ alkanes and/or chloroform. In certain more preferredembodiments, the non-polar extract is extracted from Lilium martagonbulb using hexanes, chloroform or a mixture thereof. In even morepreferred embodiments, the non-polar extract is extracted from Liliummartagon bulb using hexanes. In even more preferred embodiments, thenon-polar extract is extracted from Lilium martagon bulb usingchloroform.

In certain preferred embodiments, the extract of the invention comprisesa polar extract prepared by extracting from Lilium martagon bulb using apolar solvent comprising water, C₁-C₈ alcohols, C₁-C₈ polyols, C₁-C₈glycols, and combinations of two or more thereof. In certain morepreferred embodiments, the polar extract is an aqueous extract extractedfrom Lilium martagon bulb using water.

In certain other preferred embodiments, the extract of the inventioncomprises a combination of polar and non-polar extracts of from Liliummartagon bulb.

In certain preferred embodiments, the extract comprises a non-polarextract prepared by extracting from Lilium martagon stem using anon-polar solvent comprising one or more C₁-C₈ alkanes, C₁-C₈cycloalkanes, C₁-C₈ alkyl ethers, and/or chloroform, more preferably oneor more C₁-C₈ alkanes and/or chloroform. In certain more preferredembodiments, the non-polar extract is extracted from Lilium martagonstem using hexanes, chloroform or a mixture thereof. In even morepreferred embodiments, the non-polar extract is extracted from Liliummartagon stem using hexanes. In even more preferred embodiments, thenon-polar extract is extracted from Lilium martagon stem usingchloroform.

In certain preferred embodiments, the extract of the invention comprisesa polar extract prepared by extracting from Lilium martagon stem using apolar solvent comprising water, C₁-C₈ alcohols, C₁-C₈ polyols, C₁-C₈glycols, and combinations of two or more thereof. In certain morepreferred embodiments, the polar extract is an aqueous extract extractedfrom Lilium martagon stem using water.

In certain other preferred embodiments, the extract of the inventioncomprises a combination of polar and non-polar extracts of from Liliummartagon stem.

In certain preferred embodiments, the extract comprises a non-polarextract prepared by extracting from Lilium martagon leaves using anon-polar solvent comprising one or more C₁-C₈ alkanes, C₁-C₈cycloalkanes, C₁-C₈ alkyl ethers, and/or chloroform, more preferably oneor more C₁-C₈ alkanes and/or chloroform. In certain more preferredembodiments, the non-polar extract is extracted from Lilium martagonleaves using hexanes, chloroform or a mixture thereof. In even morepreferred embodiments, the non-polar extract is extracted from Liliummartagon leaves using hexanes. In even more preferred embodiments, thenon-polar extract is extracted from Lilium martagon leaves usingchloroform.

In certain preferred embodiments, the extract of the invention comprisesa polar extract prepared by extracting from Lilium martagon leaves usinga polar solvent comprising water, C₁-C₈ alcohols, C₁-C₈ polyols, C₁-C₈glycols, and combinations of two or more thereof. In certain morepreferred embodiments, the polar extract is an aqueous extract extractedfrom Lilium martagon leaves using water.

In certain other preferred embodiments, the extract of the inventioncomprises a combination of polar and non-polar extracts of from Liliummartagon leaves.

Applicants have recognized for certain embodiments that preferredextracts of Lilium martagon comprise one or more polyunsaturated fattyacids having a structure of formula I:R—COOH  (I)wherein R is —(CH₂)_(z)—(CH═CH—CH₂)_(n)—(CH₂)_(m)—CH₃, where n is from 1to 6, m is from zero to 6, and z is from 2 to 7. In certain preferredembodiments, R is selected from the group consisting of:—(CH₂)₇—CH═CH—CH₂—(CH₂)₆—CH₃, —(CH₂)₇—(CH═CH—CH₂)₂—(CH₂)₃—CH₃,—(CH₂)₇—(CH═CH—CH₂)₃—CH₃, and combinations of two or more thereof. Incertain more preferred embodiments, the polyunsaturated fatty acids areomega-3, omega-6 or omega-9 fatty acids or combinations of two or morethereof. Examples of omega-3 fatty acids include, but are not limitedto, α-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid,all-cis-6,9,12,15-octadecatetraenoic acid, Eicosatrienoic acid,Eicosatetraenoic acid, Clupanodonic acid, Nisinic acid, and the like.Examples of omega-6 fatty acids include, but are not limited to,linoleic acid, γ-linolenic acid, dihomo-γ-linolenic acid, arachidonicacid, Docosapentaenoic acid, Eicosadienoic acid, Docosadienoic acid,Adrenic acid, Calendic acid, and the like. Examples of omega-9 fattyacids include, but are not limited to, oleic acid, Erucic acid,Eicosenoic acid, Eicosatrienoic acid, and the like.

According to certain preferred embodiments, the extracts of Liliummartagon whole plant, flower, stem, leaves and/or bulb comprise at leastabout 0.005 weight % (wt. %) of one or more polyunsaturated fatty acidshaving a structure of formula I above. In certain embodiments, theextracts comprise from about 0.0051 to about 100 wt. % ofpolyunsaturated fatty acids having a structure of formula I, morepreferably from about 1 to about 90 wt. % of polyunsaturated fatty acidshaving a structure of formula I, and even more preferably from about 40to about 80 wt. % of polyunsaturated fatty acids having a structure offormula I. As described herein and claimed, the weight % ofpolyunsaturated fatty acids in an extract of Lilium martagon iscalculated as weight of total solids content of all polyunstatured fattyacid(s) of Formula I in the extract divided by the weight of totalsolids content of the extract times 100 to get a percent.

According to certain preferred embodiments, the extracts of Liliummartagon whole plant, flower, stem, leaves, and/or bulb comprise one ormore hydrophilic materials selected from the group consisting ofpolysaccharides, oligosaccharides, disaccharides, and combinations oftwo or more thereof. Examples of polysaccharides include, but are notlimited to, Amylose, Amylopectin, Beta-glucans, Glycans, Xylan,Arabinoxylans, glucomannans, combinations of two or more thereof, andthe like. Examples of oligosaccharides include, but are not limited to,trisaccharides such as raffinose, melezitose, maltotriose;tetrasaccharides such as acarbose, stachyose; pentasaccharides,combinations of two or more thereof, and the like. Examples ofdisaccharides include, but are not limited to, maltose, sucrose,lactose, trehalose, turanose, cellobiose, combinations of two or morethereof, and the like.

According to certain preferred embodiments, the extracts of Liliummartagon whole plant, flower, stem, leaves, and/or bulb comprise atleast about 0.005 wt. % of one or more polysaccharides,oligosaccharides, disaccharides, and combinations of two or morethereof. In certain embodiments, the extracts comprise from about 0.01wt. % to about 80 wt. % of polysaccharides, oligosaccharides,disaccharides, and combinations of two or more thereof, more preferablyfrom about 1 to about wt. %, and even more preferably from about 10 toabout 20 wt. % of polysaccharides, oligosaccharides, disaccharides, andcombinations of two or more thereof.

In certain embodiments, the Lilium martagon whole plant, flower, stem,leaves, and/or bulb comprises one or more hydrophilic materials selectedfrom the group consisting of amino acids, pyrroline derivatives,butanedioic acids and their esters, and combinations of two or morethereof. Examples of amino acids include, but are not limited to,threonine, tyrosine, cysteine, methionine, aspartic acid, asparagine,glutamic acid, glutamine, arginine, lysine, histidine, serine, glycine,valine, leucine, phenylalanine, tryptophan, proline, hydroxyproline,γ-aminobutyric acid, lanthionine, isoleucine, β-alanine, glycine,ornithine, hydroxylysine, and combinations of two or more thereof. Incertain preferred embodiments, the Lilium martagon flower extractcomprises the amino acid tyrosine. Examples of butanedioic acids andtheir esters include, but are not limited to malic acid, itatartaricacid, succinic acid, itaconic acid, hydroxyparaconic acids, their alkylesters, and combinations of two or more thereof. Examples of pyrrolinederivatives include, but are not limited to Ethyljatropham, Jatrophamand its glucosides, Citraconimide, Pyrroline-2-one and its derivativesincluding glucosides, Lilaline,3-methyl-1-(2-oxopyrrolidin-5-yl)-2,5-dihydropyrrol-2-one and itsanalogs.

According to certain preferred embodiments, the extracts of Liliummartagon whole plant, flower, stem, leaves, and/or bulb comprise atleast about 0.001 wt. % of one or more amino acids, pyrrolinederivatives, butanedioic acids and their esters, and combinations of twoor more thereof. In certain embodiments, the extracts comprise fromabout 0.0011 to about 60 wt. % of amino acids, pyrroline derivatives,butanedioic acids and their esters, and combinations of two or morethereof, more preferably from about 0.01 wt. % to about 40 wt. %, andeven more preferably from about 1 to about 20 wt. % of amino acids,pyrroline derivatives, butanedioic acids and their esters, andcombinations of two or more thereof.

According to certain embodiments of the present invention, the Liliummartagon extract preferably comprises a solids weight ratio oflipophilic materials to hydrophilic materials of about 100:0 to about10:90. As used herein, a “lipophilic material” generally refers to amaterial that has a dielectric constant of about 1 to about 15,preferably from about 2 to 15, at 22° C. (examples of lipohilicmaterials include, but are not limited to, (poly)saturated andunsaturated fatty alcohols/acids/esters and the like) and a “hydrophilicmaterial” generally refers to a material that has a dielectric constantof greater than 15 to about 90, preferably greater than 15 to about 80,and in certain more preferred embodiments, from about 35 to about 80, at22° C. (examples of hydrohilic materials include, but are not limitedto, polysaccharides, oligosaccharides, disaccharides, amino acids,pyrroline derivatives, butanedioic acids and their esters, and thelike). In certain more preferred embodiments, the extract of the presentinvention comprises a solids weight ratio of lipophilic materials tohydrophilic materials of about 90:10 to about 20:80 more preferablyabout 80:20 to about 40:60. In certain particularly preferredembodiments, the extract comprises a solids weight ratio of lipophilicmaterials to hydrophilic materials of about 80:20.

In certain embodiments, the Lilium martagon extract and/or thecomposition of the present invention may be prepared to have arelatively low amount of saturated fatty acids therein. In certainpreferred embodiments, the extract is essentially free, more preferablyfree, of one or more saturated fatty acids. In addition, in certainpreferred embodiments, the overall composition is essentially free, morepreferably free, of one or more saturated fatty acids.

In certain preferred embodiments, the extract has a weight ratio oftotal polyunsaturated fatty acids of Formula I to total saturated fattyacids (total solids wt. polyunsaturated fatty acids:total solids wt.saturated fatty acids) of about 3:1 or greater. More preferably theweight ratio of total polyunsaturated fatty acids of Formula I to totalsaturated fatty acids in the extract is from about 4:1 to about 9:1 orgreater. In certain more preferred embodiments, the weight ratio oftotal polyunsaturated fatty acids of Formula I to total saturated fattyacids is about 99:1 or greater.

In certain embodiments, the extract and/or compositions of the presentinvention may be essentially free of certain other materials. In oneembodiment, the extract is essentially free of one or more flavanoids,saponins, and/or glucosides of flavanoids or saponins. In certainembodiments, the extract and the resulting composition is essentiallyfree of flavanoids, saponins and their glucosides. For example, incertain embodiments of the present invention a polar or non-polarextract may be further extracted with, for example, methanol to removeessentially all of the flavanoids, saponins, and/or glucosides offlavanoids or saponins, and/or may be subjected to chromatographical orother methods to remove such materials. Examples of flavanoids,saponins, and/or their glucosides include, but are not limited to:Luteolin, Apigenin, Sapogenin, rutinosides, Tangeritin, Quercetin,Kaempferol, 8-(3-Methylsuccinyl) kaempferol, Myricetin, Fisetin,Isorhamnetin, Pachypodol, Rhamnazin, Hesperetin, Naringenin,Eriodictyol, Etioline, Homoeriodictyol, Taxifolin (or Dihydroquercetin),Dihydrokaempferol, Genistein, Daidzein, Glycitein, epicatechin,2-phenylethyl palmitate, Lilaline, Proanthocyanidins,3,6′-diferuloylsucrose, Helonioside A, Isorhamnetin-3-rutinoside,Kaempferol-3-O-[b-D-xylopyranosyl-(1→2)-b-D-glucopyranoside],Kaempferol-3-O-[b-D-glucopyranosyl-(1→2)-b-D-galactopyranoside], and thelike.

Any suitable amounts of Lilium martagon whole plant, flower, stem,leaves, and/or bulb extract may be used in the compositions of thepresent invention. Preferably, the compositions comprise a safe andeffective amount of Lilium martagon whole plant, flower, stem, leaves,and/or bulb extract. In certain preferred embodiments, the compositionscomprise from greater than zero to about 20% Lilium martagon wholeplant, flower, stem, leaves, and/or bulb extract. In certain otherpreferred embodiments, the compositions comprise from about 0.0001 toabout 20%, from about 0.001 to about 10%, from about 0.01 to about 5%,from about 0.1 to about 5%, or from about 0.2 to about 2% Liliummartagon whole plant, flower, stem, leaves, and/or bulb extract. Incertain other preferred embodiments, the compositions comprise fromgreater than zero to about 1%, from about 0.0001 to about 1%, from about0.001 to about 1%, or from about 0.01 to about 1 Lilium martagon wholeplant, flower, stem, leaves, and/or bulb extract. In certain otherpreferred embodiments, the compositions comprise from about 1 to about5%, preferably from about 2 to about 5% Lilium martagon whole plant,flower, stem, leaves, and/or bulb extract. As used herein, unlessotherwise specified, all percentages of ingredients in compositions areweight percent of active/solids ingredient based on the total weight ofcomposition.

In certain preferred embodiments, the compositions of the presentinvention comprise a total weight percent of 0.001 to 20 wt. % (based ontotal weight of polyunsaturated fatty acids in the total weight of theoverall composition) of polyunsaturated fatty acids having a structureof formula I (above). The polyunsaturated fatty acids of Formula I maybe introduced to the composition as part of the Lilium martagon extractand/or may be introduced to the composition independent of the Liliummartagon extract. In preferred embodiments, the Lilium martagon extractin the composition comprises at least a portion of the polyunsaturatedfatty acids of Formula I in the composition. In more preferredembodiments, the compositions of the present invention comprise a totalweight percent of 0.01 to 10 wt. %, more preferably 0.1 to 5 wt. %, andeven more preferably 0.1 to 3 wt. % or 0.5 to 5 wt. % of polyunsaturatedfatty acids of Formula I.

Any suitable carrier may be used in the compositions of the presentinvention. Preferably, for a skin care composition, the carrier is acosmetically-acceptable carrier. As will be recognized by those of skillin the art, cosmetically-acceptable carriers comprise carriers that aresuitable for use in contact with the body, in particular the skin forskin whitening applications, without undue toxicity, incompatibility,instability, irritation, allergic response, and the like. A safe andeffective amount of carrier is from about 50% to about 99.999%,preferably from about 80% to about 99.9%, more preferably from about99.9% to about 95%, most preferably from about 99.8% to about 98% of thecomposition. The carrier can be in a wide variety of forms. For example,emulsion carriers, including, but not limited to, oil-in-water,water-in-oil, water-in-oil-in-water, and oil-in-water-in-siliconeemulsions, are useful herein. These emulsions can cover a broad range ofviscosities, e.g, from about 100 cps to about 200,000 cps. Examples ofsuitable cosmetically-acceptable carriers includecosmetically-acceptable solvents and materials for cosmetic solutions,suspensions, lotions, creams, serums, essences, gels, toners, sticks,sprays, ointments, liquid washes and soap bars, shampoos, hairconditioners, pastes, foams, mousses, powders, shaving creams, wipes,patches, strips, powered patches, microneedle patches, bandages,hydrogels, film-forming products, facial and skin masks, make-up, liquiddrops, and the like. These product types may contain several types ofcosmetically-acceptable carriers including, but not limited tosolutions, suspensions, emulsions such as microemulsions andnanoemulsions, gels, solids, liposomes, other encapsulation technologiesand the like. The following are non-limitative examples of suchcarriers. Other carriers can be formulated by those of ordinary skill inthe art.

In one embodiment, the carrier contains water. In a further embodiment,the carrier may also contain one or more aqueous or organic solvents.Examples of organic solvents include, but are not limited to: dimethylisosorbide; isopropylmyristate; surfactants of cationic, anionic andnonionic nature; vegetable oils; mineral oils; waxes; gums; syntheticand natural gelling agents; alkanols; glycols; and polyols. Examples ofglycols include, but are not limited to, glycerin, propylene glycol,butylene glycol, pentalene glycol, hexylene glycol, polyethylene glycol,polypropylene glycol, diethylene glycol, triethylene glycol, caprylglycol, glycerol, butanediol and hexanetriol, and copolymers or mixturesthereof. Examples of alkanols include, but are not limited to, thosehaving from about 2 carbon atoms to about 12 carbon atoms (e.g., fromabout 2 carbon atoms to about 4 carbon atoms), such as isopropanol andethanol. Examples of polyols include, but are not limited to, thosehaving from about 2 carbon atoms to about 15 carbon atoms (e.g., fromabout 2 carbon atoms to about 10 carbon atoms) such as propylene glycol.The organic solvents may be present in the carrier in an amount, basedupon the total weight of the carrier, of from about 1 percent to about99.99 percent (e.g., from about 20 percent to about 50 percent). Watermay be present in the carrier (prior to use) in an amount, based uponthe total weight of the carrier, of from about 5 percent to about 95percent (e.g., from about 50 percent to about 90 percent). Solutions maycontain any suitable amounts of solvent, including from about 40 toabout 99.99%. Certain preferred solutions contain from about 50 to about99.9%, from about 60 to about 99%, from about 70 to about 99%, fromabout 80 to about 99%, or from about 90 to 99%.

A lotion can be made from such a solution. Lotions typically contain atleast one emollient in addition to a solvent. Lotions may comprise fromabout 1% to about 20% (e.g., from about 5% to about 10%) of anemollient(s) and from about 50% to about 90% (e.g., from about 60% toabout 80%) of water.

Another type of product that may be formulated from a solution is acream. A cream typically contains from about 5% to about 50% (e.g., fromabout 10% to about 20%) of an emollient(s) and from about 45% to about85% (e.g., from about 50% to about 75%) of water.

Yet another type of product that may be formulated from a solution is anointment. An ointment may contain a simple base of animal, vegetable, orsynthetic oils or semi-solid hydrocarbons. An ointment may contain fromabout 2% to about 10% of an emollient(s) plus from about 0.1% to about2% of a thickening agent(s).

The compositions useful in the present invention can also be formulatedas emulsions. If the carrier is an emulsion, from about 1% to about 10%(e.g., from about 2% to about 5%) of the carrier contains anemulsifier(s). Emulsifiers may be nonionic, anionic or cationic.

Lotions and creams can be formulated as emulsions. Typically suchlotions contain from 0.5% to about 5% of an emulsifier(s), while suchcreams would typically contain from about 1% to about 20% (e.g., fromabout 5% to about 10%) of an emollient(s); from about 20% to about 80%(e.g., from 30% to about 70%) of water; and from about 1% to about 10%(e.g., from about 2% to about 5%) of an emulsifier(s).

Single emulsion skin care preparations, such as lotions and creams, ofthe oil-in-water type and water-in-oil type are well-known in the artand are useful in the subject invention. Multiphase emulsioncompositions, such as the water-in-oil-in-water type or theoil-in-water-in-oil type, are also useful in the subject invention. Ingeneral, such single or multiphase emulsions contain water, emollients,and emulsifiers as essential ingredients.

The compositions of this invention can also be formulated as a gel(e.g., an aqueous, alcohol, alcohol/water, or oil gel using a suitablegelling agent(s)). Suitable gelling agents for aqueous and/or alcoholicgels include, but are not limited to, natural gums, acrylic acid andacrylate polymers and copolymers, and cellulose derivatives (e.g.,hydroxymethyl cellulose and hydroxypropyl cellulose). Suitable gellingagents for oils (such as mineral oil) include, but are not limited to,hydrogenated butylene/ethylene/styrene copolymer and hydrogenatedethylene/propylene/styrene copolymer. Such gels typically containsbetween about 0.1% and 5%, by weight, of such gelling agents.

The compositions of the present invention can also be formulated into asolid formulation (e.g., a wax-based stick, soap bar composition,powder, or wipe). The composition of the present invention can also becombined with a solid, semi-solid or dissolvable substrate (eg., a wipe,mask, pad, glove or strip).

The compositions of the present invention may further comprise any of avariety of additional cosmetically active agents. Examples of suitableadditional active agents include: additional skin lightening agents,darkening agents, anti-acne agents, shine control agents, anti-microbialagents such as anti-yeast agents, anti-fungal, and anti-bacterialagents, anti-inflammatory agents, anti-parasite agents, externalanalgesics, sunscreens, photoprotectors, antioxidants, keratolyticagents, detergents/surfactants, moisturizers, nutrients, vitamins,energy enhancers, anti-perspiration agents, astringents, deodorants,hair removers, hair growth enhancing agents, hair growth delayingagents, firming agents, hydration boosters, efficacy boosters,anti-callous agents, agents for skin conditioning, anti-celluliteagents, fluorides, teeth whitening agents, anti-plaque agents, andplaque-dissolving agents, odor-control agents such as odor masking orpH-changing agents, and the like. Examples of various suitableadditional cosmetically acceptable actives include hydroxy acids,benzoyl peroxide, D-panthenol, UV filters such as but not limited toavobenzone (Parsol 1789), bisdisulizole disodium (Neo Heliopan AP),diethylamino hydroxybenzoyl hexyl benzoate (Uvinul A Plus), ecamsule(Mexoryl SX), methyl anthranilate, 4-aminobenzoic acid (PABA), cinoxate,ethylhexyl triazone (Uvinul T 150), homosalate, 4-methylbenzylidenecamphor (Parsol 5000), octyl methoxycinnamate (Octinoxate), octylsalicylate (Octisalate), padimate O (Escalol 507), phenylbenzimidazolesulfonic acid (Ensulizole), polysilicone-15 (Parsol SLX), trolaminesalicylate, Bemotrizinol (Tinosorb S), benzophenones 1-12, dioxybenzone,drometrizole trisiloxane (Mexoryl XL), iscotrizinol (Uvasorb HEB),octocrylene, oxybenzone (Eusolex 4360), sulisobenzone, bisoctrizole(Tinosorb M), titanium dioxide, zinc oxide, carotenoids, free radicalscavengers, spin traps, retinoids and retinoid precursors such asretinol, retinoic acid and retinyl palmitate, ceramides, polyunsaturatedfatty acids, essential fatty acids, enzymes, enzyme inhibitors,minerals, hormones such as estrogens, steroids such as hydrocortisone,2-dimethylaminoethanol, copper salts such as copper chloride, peptidescontaining copper such as Cu:Gly-His-Lys, coenzyme Q10, amino acids sucha proline, vitamins, lactobionic acid, acetyl-coenzyme A, niacin,riboflavin, thiamin, ribose, electron transporters such as NADH andFADH2, and other botanical extracts such as oat, aloe vera, Feverfew,Soy, Shiitake mushroom extracts, and derivatives and mixtures thereof.

In certain preferred embodiments, the compositions of the presentinvention are skin care compositions that comprise a Lilium martagonwhole plant, flower and/or bulb extract and at least one additional skinlightening active agent. Examples of suitable additional skin lighteningactive agents include, but are not limited to, tyrosinase inhibitors,melanin-inhibiting agents, melanosome transfer inhibiting agentsincluding PAR-2 antagonists, exfoliants, sunscreens, retinoids,antioxidants, Tranexamic acid, skin bleaching agents, allantoin,opacifiers, talcs and silicas, zinc salts, and the like, and otheragents as described in Solano et al. Pigment Cell Res. 19 (550-571).

Examples of suitable tyrosinase inhibitors include but, are not limitedto, Vitamin C and its derivatives, Vitamin E and its derivatives, KojicAcid, Arbutin, resorcinols, hydroquinone, Flavones e.g. Licoriceflavanoids, Licorice root extract, Mulberry root extract, DioscoreaCoposita root extract, Saxifraga extract and the like, Ellagic acid,Salicylates and derivatives, Glucosamine and derivatives, Fullerene,Hinokitiol, Dioic acid, Acetyl glucosamine, Magnolignane, combinationsof two or more thereof, and the like. Examples of vitamin C derivativesinclude, but are not limited to, ascorbic acid and salts, AscorbicAcid-2-Glucoside, sodium ascorbyl phosphate, magnesium ascorbylphosphate, and natural extract enriched in vitamin C. Examples ofvitamin E derivatives include, but are not limited to, alpha-tocopherol,beta, tocopherol, gamma-tocopherol, delta-tocopherol, alpha-tocotrienol,beta-tocotrienol, gamma-tocotrienol, delta-tocotrienol and mixturesthereof, tocopherol acetate, tocopherol phosphate and natural extractsenriched in vitamin E derivatives. Examples of resorcinol derivativesinclude, but are not limited to, resorcinol, 4-substituted resorcinolslike 4-alkylresorcinols such as 4-butyresorcinol (rucinol),4-hexylresorcinol, phenylethyl resorcinol,1-(2,4-dihydroxyphenyl)-3-(2,4-dimethoxy-3-methylphenyl)-Propane and thelike and natural extracts enriched in resorcinols. Examples ofsalicylates include, but are not limited to, salicylic acid,acetylsalicylic acid, 4-methoxysalicylic acid and their salts. Incertain preferred embodiments, the tyrosinase inhibitors include a4-substituted resorcinol, a vitamin C derivative, or a vitamin Ederivative. In more preferred embodiments, the tyrosinase inhibitorcomprises Phenylethyl resorcinol, 4-hexyl resorcinol, orascorbyl-2-glucoside.

Examples of suitable melanin-degradation agents include, but are notlimited to, peroxides and enzymes such as peroxidases and ligninases. Incertain preferred embodiments, the melanin-inhibiting agents include aperoxide or a ligninase.

Examples of suitable melanosome transfer inhibiting agents includingPAR-2 antagonists such as soy trypsin inhibitor or Bowman-BirkInhibitor, Vitamin B3 and derivatives such as Niacinamide, Essentialsoy, Whole Soy, Soy extract. In certain preferred embodiments, themelanosome transfer inhibiting agents includes a soy extract orniacinamide.

Examples of exfolliants include, but are not limited to, alpha-hydroxyacids such as lactic acid, glycolic acid, malic acid, tartaric acid,citric acid, or any combination of any of the foregoing, beta-hydroxyacids such as salicylic acid, polyhydroxy acids such as lactobionic acidand gluconic acid, and mechanical exfoliation such as microdermabrasion.In certain preferred embodiments, the exfolliant include glycolic acidor salicylic acid.

Examples of sunscreens include, but are not limited to, avobenzone(Parsol 1789), bisdisulizole disodium (Neo Heliopan AP), diethylaminohydroxybenzoyl hexyl benzoate (Uvinul A Plus), ecamsule (Mexoryl SX),methyl anthranilate, 4-aminobenzoic acid (PABA), cinoxate, ethylhexyltriazone (Uvinul T 150), homosalate, 4-methylbenzylidene camphor (Parsol5000), octyl methoxycinnamate (Octinoxate), octyl salicylate(Octisalate), padimate 0 (Escalol 507), phenylbenzimidazole sulfonicacid (Ensulizole), polysilicone-15 (Parsol SLX), trolamine salicylate,Bemotrizinol (Tinosorb S), benzophenones 1-12, dioxybenzone,drometrizole trisiloxane (Mexoryl XL), iscotrizinol (Uvasorb HEB),octocrylene, oxybenzone (Eusolex 4360), sulisobenzone, bisoctrizole(Tinosorb M), titanium dioxide, zinc oxide, and the like.

Examples of retinoids include, but are not limited to, retinol,retinaldehyde, retinoic acid, retinyl palmitate, isotretinoin,tazarotene, bexarotene and Adapalene. In certain preferred embodiments,the retinoid is retinol.

Examples of antioxidants include, but are not limited to, water-solubleantioxidants such as sulfhydryl compounds and their derivatives (e.g.,sodium metabisulfite and N-acetyl-cysteine, glutathione), lipoic acidand dihydrolipoic acid, stilbenoids such as resveratrol and derivatives,lactoferrin, and ascorbic acid and ascorbic acid derivatives (e.g.,ascobyl-2-glucoside, ascorbyl palmitate and ascorbyl polypeptide).Oil-soluble antioxidants suitable for use in the compositions of thisinvention include, but are not limited to, butylated hydroxytoluene,retinoids (e.g., retinol and retinyl palmitate), tocopherols (e.g.,tocopherol acetate), tocotrienols, and ubiquinone. Natural extractscontaining antioxidants suitable for use in the compositions of thisinvention, include, but not limited to, extracts containing flavonoidsand isoflavonoids and their derivatives (e.g., genistein and diadzein),extracts containing resveratrol and the like. Examples of such naturalextracts include grape seed, green tea, pine bark, feverfew,parthenolide-free feverfew, oat extracts, pomelo extract, wheat germextract, Hysperedin, Grape extract, Portulaca extract, Licochalcone,chalcone, 2,2′-dihydroxy chalcone, Primula extract, porpolis, and thelike.

The additional cosmetically active agent may be present in a compositionin any suitable amount, for example, in an amount of from about 0.0001%to about 20% by weight of the composition, e.g., about 0.001% to about10% such as about 0.01% to about 5%. In certain preferred embodiments,in an amount of 0.1% to 5% and in other preferred embodiments from 1% to2%.

A variety of other materials may also be present in the compositions ofthe present invention. These include, for example, chelating agents,humectants, opacifiers, conditioners, preservatives, fragrances and thelike. The compositions may include surfactants, for example, thoseselected from the group consisting of anionic, non-ionics, amphoteric,cationic, or a combination of two or more thereof.

In certain preferred embodiments, the present invention is in the formof a substrate comprising a composition of the present invention. Anysuitable substrate may be used in the present invention. Examples ofsuitable substrates and substrate materials are disclosed, for example,in U.S. Published Application Nos. 2005/0226834 and 2009/0241242 whichare incorporated herein by reference in their entirety.

In certain preferred embodiments, the substrate is a wipe or a facialmask. Preferably, such embodiments comprise a water-insoluble substrateas such is defined in the cited references above. For certainembodiments, the water-insoluble substrate may have a size and shapesuch that it covers the face of a human user to facilitate placing thewater-insoluble substrate about the face of the user as a masksubstrate. For example, the water-insoluble mask substrate may haveopenings for a mouth, nose, and/or eyes of the user. Alternatively, thewater-insoluble substrate may have no such openings. Such aconfiguration without openings may be useful for embodiments of theinvention in which the water-insoluble substrate is intended to bedraped over a non-facial expanse of skin or if the water-insolublesubstrate is intended to be used as wipe. The water-insoluble substratemay have various shapes, such as an angular shape (e.g., rectangular) oran arcuate shape such as circular or oval.

In one embodiment of the invention, the product includes a plurality ofwater-insoluble substrates of different shapes. In one embodiment of theinvention, the product includes a first water-insoluble substrate and asecond water-insoluble substrate. The first water-insoluble substrate isshaped for application onto the forehead and the second water-insolublesubstrate is shaped for application proximate to the mouth, such asareas above and/or below the lips, the chin, and/or the cheeks. In oneembodiment of the invention, the first water-insoluble substrate is alsoapplied to the nose region of the face. The first water-insolublesubstrate may have a surface area of from about 100 cm² to about 200cm², such as from about 120 cm² to about 160 cm² and the secondwater-insoluble substrate has a surface area of from about 100 cm² toabout 300 cm², such as from about 150 cm² to about 250 cm². In oneembodiment of the invention, the water-insoluble substrate has a lowstiffness such that it may, for example, readily drape over or conformto the face or other body parts of the user.

The present invention further comprises methods of lightening the skinby applying to skin in need of skin lightening treatment an extract ofLilium martagon whole plant, flower, stem, leaves, and/or bulb, as suchextracts and embodiments thereof are described above. In certainembodiments, the method comprises applying a composition of the presentinvention comprising an extract of Lilium martagon whole plant, flower,stem, leaves, and/or bulb, as such compositions are described above invarious embodiments, to skin in need of skin lightening treatment.

The present invention may comprise application to any skin in need oftreatment on the body. For example, application may be made to any oneor more of the skin of the face, neck, chest, back, arms, axilla, handsand/or legs.

Preferably, the methods of the present invention comprise applying asafe and skin-lightening effective amount of Lilium martagon wholeplant, flower, stem, leaves, and/or bulb extract to the skin. In certainpreferred embodiments, the methods comprise applying from greater thanzero to about 20% Lilium martagon extract to the skin in need. Incertain other preferred embodiments, the methods comprise applying fromabout 0.0001 to about 20%, from about 0.001 to about 10%, from about0.01 to about 5%, from about 0.1 to about 5%, or from about 0.2 to about2% Lilium martagon extract to the skin in need. In certain otherpreferred embodiments, the methods comprise from greater than zero toabout 1%, from about 0.0001 to about 1%, from about 0.001 to about 1%,or from about 0.01 to about 1% Lilium martagon extract to the skin. Incertain other preferred embodiments, the methods comprise applying fromabout 1 to about 5%, preferably from about 2 to about 5% Lilium martagonextract to the skin.

Any suitable method of applying the extract to the skin in need may beused in accord with the present invention. For example, the extract maybe applied directly from a package to the skin in need, by hand to theskin in need, or may be transferred from a substrate such as a wipe ormask, or a combination of two or more thereof. In other embodiments, theextract may be applied via a dropper, tube, roller, spray, patch oradded to a bath or otherwise to water to be applied to the skin, and thelike.

In certain embodiments, the methods of the present invention furthercomprise the step of leaving the Lilium martagon whole plant, flowerand/or bulb extract in contact with the skin for period of time. Forexample, in certain preferred embodiments after application, the extractis left in contact with the skin for a period of about 15 minutes orgreater. In certain more preferred embodiments, the extract is left incontact with the skin for about 20 minutes or greater, more preferablyabout 1 hour or greater.

In certain embodiments, the method of the present invention comprises aregimen comprising applying the Lilium martagon whole plant, flowerand/or bulb extract to skin multiple times over a selected period oftime. For example, in certain embodiments, the present inventionprovides a method of skin lightening comprising applying to skin in needof skin lightening a composition comprising a Lilium martagon wholeplant, flower and/or bulb extract once or twice daily for at least 12weeks, preferably at least 8 weeks and more preferably for at least 2weeks.

In certain preferred embodiments, the methods of the present inventioncomprise applying at least two different compositions or productscomprising Lilium martagon whole plant, flower and/or bulb extract tothe skin. For example, the methods may comprise applying a firstcomposition comprising Lilium martagon whole plant, flower and/or bulbextract to skin in need of skin lightening followed by applying a secondcomposition comprising Lilium martagon whole plant, flower and/or bulbextract, but that is otherwise different from the first composition, tothe skin in need of skin lightening. In certain preferred embodiments,the first and second composition may be independently selected from thegroup consisting of lotions, cleansers, masks, wipes, creams, serums,gels, and the like. In certain preferred embodiments, at least one ofthe first and second compositions is a cleanser, lotion, cream, essence,or serum and the other is a facial mask or wipe. In certain otherpreferred embodiments, at least one of the first and second compositionsis a cleanser and the other is a lotion or cream.

In certain other preferred embodiments, the method comprises applying atleast three products comprising Lilium martagon whole plant, flowerand/or bulb extract to skin in need of skin lightening. Preferably suchthree products are selected from the group consisting of cleansers,lotions, creams, essences, and facial masks.

EXAMPLES

The following test methods were used in the Examples:

Melanin Synthesis Inhibition Test

Control samples of B16(F10) murine melanoma cells were prepared andharvested as indicated below, but without addition of any test sampleand without exposure to UVB (untreated control). Other control sampleswere prepared and harvested as indicated below without addition of testsample and exposed to UVB as described below (treated control). One ormore samples of B16(F10) cells were prepared and each pre-treated with atest sample (e.g. E1) followed by UVB exposure as described below. Upontreatment, UVB stimulated melanogenesis in the cells and test compoundswere evaluated based on their ability to inhibit or slow down the rateof melanogenesis. The cells were lysed for protein measurement at 595 nmand melanin content at 470 nm. The potency of the test compounds weredetermined by comparing the % inhibition achieved by the test compoundsagainst the treated control.

Testing Procedure:

On a first day, murine melanoma B16(F10) cells were seeded in 60 mmplates with a density of ˜1 million cells per plate and incubated for 48hrs at 37° C., 5% CO₂. On day 2, the cells with a confluency rate of90-100% were treated with test compound at a predetermined concentration(e.g. 25 μg/mL) for two hours (for test compound samples only) followedby exposure to UVB 20 mJ/cm² (for test samples and treated control). Thecells were harvested on day 3 (24 h post UVB irradiation for testsamples and treated control) and lysed in protein lysis buffer (50 mMTris, pH 8, 2 mM EDTA, 150 mM NaCl, and 1% Triton X 100—a nonionicsurfactant purchased from BioRad Cat.#: 161-0407), and centrifuged. Theresulting supernatant was mixed well with a protein dye assay (Bio-radprotein assay reagent) and a spectrophotometer (Molecular DevicesVERSAmax) was used to determine the optical density (protein assay OD)of the sample at 595 nm. The cell pellet remaining after removal of thesupernatant was dissolved in alkaline DMSO buffer, and the resultingsolution used for melanin absorbance assay at 470 nm to determinemelanin assay OD.

Three samples each of the untreated control, treated control, and eachtest sample were made and the Melanin and Protein OD measured for each.The normalized melanin for each untreated control (3 samples), treatedcontrol (3 samples) and test sample (3 samples for each test compound)was calculated via the following equation:Normalized Melanin=melanin assay OD/protein assay OD.

The average normalized Melanin of the untreated controls was calculated(sum of the three calculated values/3), and the average normalizedMelanin of the treated controls similarly calculated.

The Induction value of the Control was calculated via the equation:Induction value of Control=average normalized Melanin of treatedcontrol−average normalized Melanin of untreated control.

The Induction value with each test sample is then calculated via theequation:Induction value with Test Sample=normalized Melanin of the testsample−average normalized Melanin of untreated control.

The Inhibition % for each test sample is then calculated via theequation:100×[(Induction value of Control−Induction value with TestSample)/Induction value of Control]. The average Inhibition % iscalculated as the sum of the three resulting Inhibition % values foreach test sample divided by three.

The calculation sequence for % inhibition are explained by a theoreticalexample, see the following table.

Average normalized melanin 0.98 Untreated control Average normalizedmelanin 2.56 UVB treated control Induction value of control 2.56 − 0.98= 1.58 Average normalized melanin 1.04 Test sample Induction value withTest 1.04 − 0.98 = 0.06 sample Inhibition % for Test sample [(1.58 −0.06)/1.58] × 100 = 96.20%Skin Epidermal Equivalents Model as a Skin Lightening Test (ΔL)

Skin epidermal equivalent tissues are available commercially fromMatTek's MelanoDerm™ System and were used for the following tests.MatTek's MelanoDerm™ System consists of normal, human-derived epidermalkeratinocytes (NHEK) and melanocytes (NHM) which have been cultured toform a multilayered, highly differentiated model of the human epidermis.Specifically, MEL-300-B tissues, each 9 mm in diameter were used in thefollowing tests.

The test materials prepared in an appropriate vehicle and testedconcentrations were applied topically to the skin model daily and theexperiment lasted for 8 days. Measurement was taken on day 9.

The macroscopic and microscopic visual tissue darkening end points weremeasured by taking pictures with a digital camera. The Degree ofLightness for each tissue (L-Value) was measured using aspectrophotometer (Konica Minolta CM-2600d). The ΔL (degree of lightnessas compared to control) for each test sample is calculated as perfollowing formula:ΔL=L-value of treated sample−L-value of control sample.

According to certain preferred embodiments, the compositions of thepresent invention are effective to achieve a ΔL in accord with this testof greater than zero. More preferably, the compositions of the presentinvention are effective to achieve a ΔL of about 0.15 or greater, morepreferably about 0.5 or greater, more preferably about 1 or greater,more preferably about 1.5 or greater, and more preferably about 2 orgreater.

Cell Viability Test

Cell Viability of the tissue during experiment was evaluated using theMTT assay described as follows. The MTT Tissue Viability Assay is acolorimetric assay system that measures the reduction of a yellowMethylthiazolyldiphenyl-tetrazolium bromide (MTT) into an insolublepurple product by the mitochondria of viable cells.

The skin epidermal tissues used previously to determine degree oflightness for each test material and of untreated tissues were used todetermine percent viable cells remaining at the end of the experiment.The skin epidermal tissues after degree of lightness test were incubatedwith MTT reagent for 3 h. After incubation extraction buffer is added tolyse the cells and allowed to continue overnight. Samples are read usinga plate reader at a wavelength of 570 nm and compared against untreatedcontrol and expressed in % Cell Viability as of control. A reduction of≧30% cell viability as of control consider as a significant indicationof cell cytotoxicity caused by the test materials. The amount of purplecolor produced is directly proportional to the number of viable cells.

Example 1 Preparation of Lilium Martagon Flower Extracts (E1-E4)

The extracts were prepared as follows: dry powder of Lilium martagonflowers, obtained from Prisna, was suspended with solvent (as shown inTable 1) in an approximate 1:10 ratio (raw material/solvent). Thesuspension was stirred for 12 h at room temperature. The supernatant wasthen removed by filtration. Solvent was evaporated under reducedpressure in an evaporator at 30-40 deg C.

TABLE 1 E1-E4 extracts obtained from Lilium martagon flower dry powder.Flower Extract Solvent E1 Hexane E2 Water E3 Methanol E4 ChloroformHPLC analysis of E1 and E4 revealed that they are mainly composed oflipids (at least 50% or more) specifically unsaturated omega fatty acidsand their esters. A number of omega fatty acids and saturated fattyacids identified from E1 & E4, e.g. Linoleic acid, Linolenic acids,triglycerides, and palmitic acid. Extracts E2 and E3 are mainly composedof polar components with no or little retention on the C18 column andalso did not show any lipids.

Example 2 Lilium Martagon Bulb Extracts (E5-E8)

Extracts E5-E7 were prepared as follows: dry powder of Lilium martagonbulbs, obtained from Prisna, was suspended with solvent (as shown inTable 2) in an approximate 1:10 ratio (raw material/solvent). Thesuspension was stirred for 12 h at room temperature. The supernatant wasthen removed by filtration. Solvent was evaporated under reducedpressure in an evaporator at 30-40 deg C. E8 was a non-polar extractobtained directly from Prisna, Netherlands.

TABLE 2 E5-E7 extracts obtained from Lilium martagon bulb dry powder.Bulb Yield Extract Solvent (%) E5 Hexane 0.57 E6 Water 28.2 E7 Methanol12.9

HPLC analysis of E5 revealed that the extract mainly composed of lipids(at least 50% or more) specifically unsaturated omega fatty acids andtheir esters. Extract E8 has significant amounts of polar components andlipids in an approximate ratio of 1:3-1:4, resp. The polar componentspresent in E8 shows some retention on C18 and the lipids profile isdifferent from E5. A number of omega fatty acids and saturated fattyacids were identified from E5 & E8, e.g. Linoleic acid, Linolenic acids,triglycerides, and palmitic acid. Extracts E6 and E7 are mainly composedof polar components with no or very little lipids.

Example 3 Preparation of Lilium Martagon Leaf Extracts (E9-E12)

Extracts were prepared as follows: dry powder of Lilium martagon leaves,obtained from Prisna, was suspended with solvent (as listed in Table 3)in an approximate 1:10 ratio (raw material/solvent). The suspension wasstirred for 12 h at room temperature. The supernatant was then removedby filtration. Solvent was evaporated under reduced pressure in anevaporator at 30-40 deg C.

TABLE 3 E9-E12 extracts obtained from Lilium martagon leaves dry powder.Flower Extract Solvent E9 Hexane E10 Water E11 Methanol E12 Chloroform

Example 4 Preparation of L. Martagon Plant, Bulb, Flower, or Leaf SerumExtracts

In another example plant serum extracts are prepared from whole plant,whole bulb, whole flower cell juice or mixtures of two or more thereof.The detailed method of extraction is published in patent literature U.S.Pat. No. 7,442,391 B2. This method provides a unique opportunity tomaximize the melanogenesis inhibition by selectively concentratingdesired bioactives in one extract.

Example 4 Determination of Melanin Synthesis Inhibition Activity

Extracts E1-E12 were tested in B16 cells for UVB induced melaninsynthesis inhibition in accord with the Melanin Synthesis InhibitionTest. The resulting bioactivity data as IC₅₀ values for extracts E1-E12are listed in Table-4.

TABLE 4 UVB Induced Melanin Synthesis Inhibition Data Part of L.martagon UVB Melanin Synthesis Inhibition, Extract used IC50 (μg/mL) E1Flower 80 E2 Flower 400 E3 Flower 400 E4 Flower 40 E5 Bulb 80 E6 Bulb700 E7 Bulb >500 E8 Bulb 8 E9 Leaf >100 E10 Leaf >500 E11 Leaf >500 E12Leaf >100

Extracts E1-E12 were also tested for mushroom tyrosinase enzymeinhibition up to 0.1% and found no significant activity for any extract.None of the extracts from Lilium martagon flower, bulb, or leaf is atyrosinase inhibitor.

Example 5 Determination of Melanin Synthesis Inhibition Activity in SkinEpidermal Equivalent Model

Extract E8 was tested for its skin lightening efficacy in a 3D SkinEpidermal Model for melanin synthesis inhibition in accord with the SkinEpidermal Equivalents Model as a skin Lightening Test. The test resultsconfirmed the lightening efficacy of E8 and this can be used incosmetics as a skin lightening agent. The data from 3D Skin EpidermalEquivalent tissues are recorded in Table 5.

TABLE 5 Degree of lightness as a measure of melanin synthesis inhibitionin Skin Epidermal Equivalent Model with topical dose of Lilium martagonbulb extract, E8. Plant Conc. Used Degree of Lightness Standard ExtractPart used (%) (ΔL value) Deviation E8 bulb 1 0.53 0.39 2 1.8 0.17 5 4.10.52

Example 6 Preparation of Composition

A typical product formula in cream with skin lightening actives fromLilium martagon is made using the ingredients in Table 6 as follows.

TABLE 6 Item Ingredient/ % # Function Trade/INCI Name Weight 1 PurifiedWater Water Balance 2 EDTA BD Disodium EDTA 0.10 3 Emulsifiers PemulenTR-1, Brij72, Brij 721, 4.90 Lanette 22, Amphisol K, Simulgel EG 4Thickeners Carbopol Ultrez 20, Xanthan gum 0.20 180 5 HumectantsButylene Glycol, Glycerin 9.00 6 Skin Prodew 300, Cetiol SB-45, Edenor15.75  Conditioning ST 1 MY, Miglyol 812N, Finsolve Agent TN, DC 200 50cps, DC 345 Fluid, DC 1403, SP-500 7 Chlorohexidine ChlorohexidineDigluconate 0.25 Digluconate 20% 8 Turk's Cap Lilium martagon flowerextract 1.00 Lily Extract 9 Preservatives Methyl Paraben, Ethyl paraben,0.60 Propyl Paraben 10 Neutralizing Base Sodium hydroxide As per need 11Hydrolite-5 Pentylene Glycol 1.00The ingredients are mixed as per standard procedures. A brief generalprocedure is described here for guidance.Premix A: Dissolve Lilium martagon flower extract in butylene glycol andwaterPremix B: Mix Glycerin and Xanthan 180 until a uniform mixture isachievedPremix C: Disperse SP 500 in Butylene glycolWater Phase:

-   -   Add water into the vessel, begin agitation, add EDTA BD and mix        until uniform    -   Sprinkle in Pemulen TR-1 and Carbopol Ultrez 20 and mix until a        translucent mixture is obtained    -   Add Prodew 300, Butylene glycol, and Xantural Premix B until        uniform    -   Start heating to 80-83° C.    -   At 70-75° C., add methyl paraben and mix until uniform    -   At 80° C., add sodium hydroxide to neutralize the water phase,        Hold Temperature until phasing        Oil Phase:

Mix Miglyol 815, Finsolve TN, Lanette 22, Edenor ST1 MY, Brij 721,Cetiol SB45, Ethyl paraben, Propyl paraben, and heat to 80° C., checkthat a clear melt is achieved before mix for 20 minutes. At 80° C., addAmphisol K and mix until uniformly dispersed. Hold the temperature at80-83° C. until phasing.

Phasing:

-   -   Add Oil phase to water phase under homogenization    -   Add Simulgel EG and mix until uniform. Do not proceed until        thickening effect is observed.    -   Start Cooling to 60-65° C.    -   At 60-65° C., slowly add Premix A.    -   At 55-60° C., add DC 200 50 cst, DC 345 and DC 1403 and mix        until uniform    -   At 45° C., add Premix C    -   At below 35° C., add Hydrolite 5, Chlorohexidine digluconate,        and mix until uniform and homogenize the batch for 5 minutes.

Example 7 Preparation of Composition

Another composition according to the invention was prepared using theingredients shown in the following Table 7.

TABLE 7 Serial # INCI Name Trade Name Percentage 1 WATER PURIFIED WATERBalance 2 Xanthan Gum Keltrol CG 0.16 3 Edetate Disodium Versene NA 0.154 White Petrolatum Perfecta 5 5 Medium Chain Triglyceride Labrafac CC0.75 6 Glycerin GLYCEROL 5.50 7 Ricinus Communis Seed Oil Castor Oil 1.88 Cetyl Alcohol, NF Lanette 16 2.2 9 Emulsifying Wax, NF PolaWax, NF 1.510 Cocoa Butter Cocoa Butter, NF 2 11 Glyceryl Stearate SE GlycerylStearate SE 3.00 12 Glyceryl Stearate/PEG 100 Lexemul 561 5.00 Stearate13 Diazolidinyl Urea Germall II 0.25 14 Lilium martagon extract — 5.00(5% active) 15 Iodopropynyl Butylcarbonate Glycacil L 0.1The above composition was prepared as follows:Water Phase

-   -   Step 1. Charge Purified Water into the main container at a        temperature of 20-40° C.    -   Step 2. Add the Xanthan Gum NF to the main container. * Note: If        Xanthan Gum is lumpy use 30 mesh screen.    -   Step 3. Rinse the wall of the main container with Purified Water        to remove any Xanthan Gum from the walls.    -   Step 4. Mix the batch for 15-25 minutes. Check hydration of the        gum and proceed if acceptable.    -   Step 5. Continue mixing and add Glycerin USP Special and Edetate        Disodium USP    -   Step 6. Start heating the batch to 65° C. (63-67° C.) and        continue mixing.        Oil Phase    -   Step 1. Into a clean suitable phase container add the following        chemicals in this order: Medium Chain Triglycerides, Castor Oil,        Cocoa Butter, and Premelted Petrolatum USP    -   Step 2. Set the oil phase temperature to 65° C. (63-67° C.) and        start mixing at medium speed.    -   Step 3. While heating the batch to 65° C., add the following        chemicals in this order, allowing each to dissolve before adding        the next: Glyceryl Stearate SE, Cetyl Alcohol, Emulsifying Wax,        and Glyceryl Stearate.    -   Step 4. When the temperature reaches 65° C. (63-67° C.) mix for        15-25 minutes        phasing    -   Step 1. When both phases are homogenous and at a temperature of        63-67° C., transfer the oil phase to the water phase while        mixing the water phase at medium speed.    -   Step 2. When transfer is completed, rinse oil phase tank with        Purified Water. Heat rinsings to 63-67° C. and add it to the        main container.    -   Step 3. Mix the batch for 10-20 minutes    -   Step 4. Turn on cooling and cool the batch to 40° C. (38-42°        C.).    -   Step 5. When temperature is 48-50° C. increase mixing speed to        medium-high.    -   Step 6. Add Lilium martagon extract (5% active)    -   Step 7. When temperature is at 44° C. or lower add the        Diazolidinyl Urea Premix.    -   Step 8. Add Iodopropyl Butylcarbamate.    -   Step 9. Mix the batch for 5-10 minutes.    -   Step 10. If required, QS the batch with Purified Water.    -   Step 11. Continue mixing and start cooling of batch to 32-34° C.    -   Step 12. When the batch reaches 33° C. (32-34° C.) turn off        mixing and stop cooling.        Diazolidinyl Urea (Germall II) Premix    -   Step 1. Into a stainless steel premix tank add Purified Water.    -   Step 2. Start mixing the water and add Diazolidinyl Urea.    -   Step 3. Mix for an additional 10-20 minutes to dissolve        completely.    -   Step 4. Hold the premix for addition to the batch.

What is claimed is:
 1. A composition comprising an extract comprising anonpolar Lilium martagon flower extract, a non-polar Lilium martagonbulb extract, or a combination or two or more thereof, a carrier, and amaterial selected from the group consisting of surfactants, chelatingagents, emollients, humectants, conditioners, preservatives, opacifiers,fragrances, and combinations of two or more thereof.
 2. The compositionof claim 1 wherein said non-polar extract was extracted using one ormore solvents selected from the group consisting of C1-C8 alkanes andchloroform.
 3. The composition of claim 1 wherein said extract comprisesa non-polar extract of Lilium martagon bulb.
 4. The composition of claim1 wherein said extract comprises a non-polar extract of Lilium martagonflower.
 5. The composition of claim 1 wherein said composition comprisesfrom greater than zero to about 20% of Lilium martagon extract.
 6. Thecomposition of claim 1 wherein said composition comprises from about0.01 to about 5% of the Lilium martagon extract.
 7. The composition ofclaim 1 wherein said composition is in the form of a solution,suspension, lotion, cream, serum, gel, stick, spray, ointment, liquidwash, soap bar, shampoo, hair conditioner, paste, foam, powder, mousse,shaving cream, hydrogel, or film-forming product.
 8. The composition ofclaim 1 wherein said composition further comprises an additional skinlightening active agent.
 9. The composition of claim 8 wherein saidadditional skin lightening agent is selected from the group consistingof Phenylethyl resorcinol, 4-hexyl resorcinol, α-arbutin, Kojic acid,Nivitol, ascorbyl-2-glucoside, soy extract, niacinamide, andcombinations of two or more thereof.
 10. The composition of claim 1wherein said carrier comprises an emulsion.
 11. A composition comprisingan extract selected from the group consisting of non-polar Liliummartagon flower extracts, non-polar Lilium martagon bulb extracts, andcombinations or two or more thereof, and an additional skin lighteningactive agent.
 12. The composition of claim 11 wherein said additionalskin lightening agent is selected from the group consisting ofPhenylethyl resorcinol, 4-hexyl resorcinol, α-arbutin, Kojic acid,Nivitol, ascorbyl-2-glucoside, soy extract, niacinamide, andcombinations of two or more thereof.
 13. The composition of claim 11wherein said composition comprises from about 0.001 to about 5% of thePaulownia tomentosa wood extract.
 14. The composition of claim 13further comprising at least one material selected from the groupconsisting of surfactants, chelating agents, humectants, conditioners,preservatives, opacifiers, fragrances, and combinations of two or morethereof.
 15. A facial mask comprising a mask substrate and a compositionof claim
 1. 16. A facial mask comprising a mask substrate and acomposition of claim
 11. 17. A facial mask comprising a mask substrateand a composition of claim 14.